Invivocue was formed as a joint venture between Invitrocue, an innovative life sciences company providing in vitro liver models for drug toxicology testing, as well as 3D patient-derived organoid technology for personalised oncology, and Dr Chen Qing Feng, a Principal Investigator at A*STAR Singapore, Institute of Molecular and Cell Biology, whose research expertise focused on humanised mouse models for various disease applications.
Invivocue’s proprietary HiMice are a humanised mouse model with a stably reconstituted human immune system. As HiMice express the human immune system, they are an ideal in vivo animal model for research in human immunology, oncology, inflammation and infectious diseases.
|IL-15||Improve T-cell and NK-cell differentiation and proliferation|
|GM-CSF||Improved granulocyte, monocyte, macrophage and eosinophils differentiation|
|IL-4||Increased T and B lymphocyte proliferation|
|IL-3||Improved proliferation of a broad range of hematopoietic cell types|
|M-CSF||Improved macrophage differentiation and proliferation|
|IL-7||Increase T-cell development|